Hsbc Holdings PLC Purchases 3,279 Shares of Quanterix Co. (NASDAQ:QTRX)

Hsbc Holdings PLC lifted its holdings in Quanterix Co. (NASDAQ:QTRXFree Report) by 34.7% during the second quarter, HoldingsChannel reports. The firm owned 12,738 shares of the company’s stock after purchasing an additional 3,279 shares during the period. Hsbc Holdings PLC’s holdings in Quanterix were worth $164,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Lord Abbett & CO. LLC increased its position in Quanterix by 22.9% in the 1st quarter. Lord Abbett & CO. LLC now owns 1,757,153 shares of the company’s stock worth $41,398,000 after buying an additional 326,876 shares during the period. Superstring Capital Management LP bought a new position in Quanterix during the fourth quarter worth $1,962,000. Williams Jones Wealth Management LLC. bought a new position in Quanterix during the first quarter worth $1,327,000. Easterly Investment Partners LLC raised its stake in Quanterix by 551.1% during the 1st quarter. Easterly Investment Partners LLC now owns 78,734 shares of the company’s stock valued at $1,855,000 after purchasing an additional 66,642 shares during the last quarter. Finally, Harbor Capital Advisors Inc. grew its position in Quanterix by 772.3% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 83,941 shares of the company’s stock worth $1,109,000 after purchasing an additional 74,318 shares during the last quarter. Institutional investors and hedge funds own 86.48% of the company’s stock.

Quanterix Stock Up 0.1 %

Shares of QTRX opened at $11.90 on Friday. Quanterix Co. has a 12 month low of $10.50 and a 12 month high of $29.70. The stock has a market cap of $455.41 million, a price-to-earnings ratio of -12.40 and a beta of 1.36. The company has a 50-day moving average price of $12.94 and a two-hundred day moving average price of $15.38.

Quanterix (NASDAQ:QTRXGet Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.02). Quanterix had a negative return on equity of 11.52% and a negative net margin of 30.71%. The company had revenue of $34.38 million for the quarter, compared to the consensus estimate of $34.19 million. During the same quarter last year, the business earned ($0.16) EPS. Equities research analysts expect that Quanterix Co. will post -0.88 EPS for the current fiscal year.

Insider Transactions at Quanterix

In other news, Director David R. Walt acquired 47,000 shares of the company’s stock in a transaction dated Tuesday, August 20th. The stock was bought at an average price of $13.29 per share, with a total value of $624,630.00. Following the completion of the acquisition, the director now owns 1,487,342 shares in the company, valued at approximately $19,766,775.18. This represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. 6.90% of the stock is owned by insiders.

Analysts Set New Price Targets

QTRX has been the subject of several research reports. TD Cowen reduced their target price on shares of Quanterix from $17.00 to $15.00 and set a “hold” rating for the company in a research note on Friday, August 9th. The Goldman Sachs Group lowered their price objective on Quanterix from $35.00 to $24.00 and set a “buy” rating on the stock in a research report on Tuesday, July 9th. Finally, Scotiabank reduced their target price on Quanterix from $32.00 to $28.00 and set a “sector outperform” rating for the company in a research report on Monday, August 12th.

Get Our Latest Research Report on Quanterix

Quanterix Profile

(Free Report)

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.

Recommended Stories

Want to see what other hedge funds are holding QTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quanterix Co. (NASDAQ:QTRXFree Report).

Institutional Ownership by Quarter for Quanterix (NASDAQ:QTRX)

Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.